ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Prognostic significance of IKZF1 alterations in acute B-lymphoblastic leukemia and the choice of transplantation strategy].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene alterations in Ikaros family zinc finger protein 1 (IKZF1) are common genetic abnormalities in B-cell acute lymphoblastic leukemia (B-ALL) and are closely associated with an increased risk of relapse and poor prognosis. In this study, the biological functions of the IKZF1 gene and the clinical significance of its various mutation types were systematically elaborated. Accordingly, a comprehensive clinical decision-making framework spanning from diagnosis to post-transplantation management was constructed. This framework provides an in-depth analysis of the pivotal role of immunotherapy as a "bridge" to transplantation, innovatively proposes an "MRD clearance kinetics" -guided model for deciding on transplantation modalities (allogeneic versus autologous), and defines proactive post-transplantation intervention strategies based on MRD monitoring. Furthermore, this review aims to provide a clear and actionable blueprint for individualized therapy for B-ALL patients with IKZF1 alterations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.